IMRN - Immuron Moving to Phase 3 Clinical Trials following Positive Travelan Results

2024-03-07 06:52:16 ET

DENVER, Colo., Mar 07, 2024 ( 247marketnews.com )- Immuron Limited (NASDAQ: IMRN ) reported, this morning, that the interim topline results confirm that a single daily dose of Travelan is effective in prevention of moderate to severe diarrhea following challenge with enterotoxigenic Escherichia coli (ETEC).

IMRN is now trading at $3.69, up $1.95 (+112.07%), on 2.1M shares.

Immuron was awarded $3.43 million funding by the U.S. Department of Defense, in January 2022, to perform a randomized double-blind placebo-controlled phase 2 controlled human infection model (CHIM) study to assist with evaluating a dosing regimen that is most suited to deployed US troops visiting developing countries. Healthy volunteers were recruited and randomly assigned to receive a single daily oral dose of 1200 mg of Travelan or placebo. Dosing commenced 2 days prior to challenge with ETEC strain H10407 and continued for 7 days. ClinicalTrials.gov Identifier: NCT05933525.

Immuron is now proceeding to Phase 3 registration strategy with the FDA.

The post Immuron Moving to Phase 3 Clinical Trials following Positive Travelan Results appeared first on 24/7 MarketNews .

For further details see: